Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (UV, formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (UV, formaldehyde inactivated)
Accession Number
DB14439
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Active Moieties
NameKindUNIICASInChI Key
Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)unknownV5129EM0FRNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FlulavalInfluenza B virus B/Brisbane/60/2008 hemagglutinin antigen (UV, formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (UV,formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (UV,formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularID Biomedical Corporation of Quebec2009-07-272009-07-10US flag
Flulaval 2010/2011Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (UV, formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (UV, formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (UV, formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularID Biomedical Corporation of Quebec2010-07-292010-07-23US flag

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
X1415B53PG
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingBasic ScienceFlu caused by Influenza1
4RecruitingPreventionAdverse Event Following Immunization / Birth Outcomes / Safety1
3CompletedPreventionFlu caused by Influenza5
2CompletedPreventionFlu caused by Influenza1
2CompletedPreventionRespiratory Tract Diseases / Respiratory Tract Infections (RTI) / RNA Virus Infections / Virus Diseases2
1CompletedPreventionFlu caused by Influenza2
1CompletedPreventionInfluenza, Human1
1, 2CompletedPreventionEgg Allergy / Eligible for Vaccination Against Influenza1
Not AvailableActive Not RecruitingNot AvailableAstrocytomas / Gliomas / Oligodendrogliomas1
Not AvailableCompletedBasic ScienceImmune Response1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on July 05, 2018 12:02 / Updated on June 12, 2020 10:53